Miles H. Prince

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma.

Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma.

Journal: Future oncology (London, England)
Published: July 17, 2025

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.

Journal: The Lancet. Oncology
Published: September 28, 2023

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.

Journal: Transplantation and cellular therapy
Published: March 14, 2022

Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data.

Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data.

Journal: European journal of cancer (Oxford, England : 1990)
Published: October 15, 2021

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.

Journal: Blood cancer journal
Published: April 01, 2021

Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Journal: The British journal of dermatology
Published: April 29, 2019

Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma.

Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma.

Journal: Oncotarget
Published: July 29, 2018

Detection of clinically relevant early genomic lesions in B-cell malignancies from circulating tumour DNA using a single hybridisation-based next generation sequencing assay.

Detection of clinically relevant early genomic lesions in B-cell malignancies from circulating tumour DNA using a single hybridisation-based next generation sequencing assay.

Journal: British journal of haematology
Published: September 08, 2017

Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.

Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.

Journal: Journal of translational medicine
Published: May 31, 2016

A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.

A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.

Journal: Oncotarget
Published: March 16, 2016

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.

Journal: PLoS pathogens
Published: June 27, 2014
Showing 1-11 of 11

Last Updated: 09/26/2026